← Back to Search

Enzyme

Latiglutenase for Celiac Disease

Phase 2
Waitlist Available
Led By David Maahs, MD
Research Sponsored by Entero Therapeutics
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 6 months
Awards & highlights

Summary

This trial studies people with both Type 1 diabetes and celiac disease who have been on a gluten-free diet for a significant period. The goal is to see if avoiding gluten helps manage both conditions better. By not eating gluten, these patients can prevent their immune system from damaging their intestines, which might also help control their diabetes.

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~6 months
This trial's timeline: 3 weeks for screening, Varies for treatment, and 6 months for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.
Primary study objectives
Symptom Severity Reduction

Trial Design

2Treatment groups
Active Control
Placebo Group
Group I: LatiglutenaseActive Control1 Intervention
IMGX003
Group II: PlaceboPlacebo Group1 Intervention
Placebo

Find a Location

Who is running the clinical trial?

Entero TherapeuticsLead Sponsor
9 Previous Clinical Trials
397 Total Patients Enrolled
2 Trials studying Celiac Disease
123 Patients Enrolled for Celiac Disease
Immunogenics, LLCIndustry Sponsor
3 Previous Clinical Trials
202 Total Patients Enrolled
3 Trials studying Celiac Disease
202 Patients Enrolled for Celiac Disease
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)NIH
2,410 Previous Clinical Trials
4,324,878 Total Patients Enrolled
3 Trials studying Celiac Disease
441 Patients Enrolled for Celiac Disease
~3 spots leftby Sep 2025